Phase 1 HIV and AIDS Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have HIV-1 infection.
• People who have been continuously taking HIV treatment (antiretroviral therapy) for at least 48 months.
• People whose immune cell count (CD4+ cells) was above 450 cells/mm³ when tested within the past 12 months.
• People whose HIV virus level in the blood has been undetectable for more than 36 months, including at a test done within the past 90 days.
• People whose recent blood tests (within the past 90 days) show normal levels of white blood cells, red blood cells, and platelets.
• People whose recent blood tests show that liver-related values are within acceptable ranges.
• People whose recent blood tests show no signs of active Hepatitis B infection (with one exception: people who show signs of past Hepatitis B infection but also have protective antibodies may still be eligible — confirm with trial site).
• People whose recent blood tests show no active Hepatitis C infection, or if an initial Hepatitis C test was positive, a follow-up test confirmed no active virus.
• People whose kidney function, measured by a specific blood or urine test within the past 90 days, meets the required level.
• People whose heart electrical activity test (ECG) at the screening visit shows a normal reading below 450 milliseconds.
• People who can become pregnant must have a negative pregnancy test at screening and again within 48 hours before starting the study.
• People of any sex who could cause or become pregnant must agree to use at least two effective forms of contraception during the study and for 60 days after the last dose of the study drug.
• People who are able to swallow tablets without difficulty.
• People who are willing and able to give informed consent (or have a legal representative do so on their behalf).
• People who are willing and able to stay on the same HIV treatment throughout the entire study.

Who may not be able to join:

• People whose HIV virus level was already very low (below 2,000 copies/mL) before starting HIV treatment, suggesting their body naturally controls the virus.
• People who started HIV treatment during the very early (acute) stage of HIV infection.
• People whose HIV virus has developed resistance to drugs, leaving no backup HIV treatment options available.
• People who are currently pregnant, breastfeeding, or planning to become pregnant during the study.
• People who were hospitalised or had surgery within the 90 days before entering the study.
• People who needed intravenous (drip) antibiotics for an infection within the 90 days before entering the study.
• People with any evidence of liver damage or liver disease.
• People with a history of digestive or gastrointestinal conditions that lasted more than 180 days, or who currently have such conditions.
• People with an active cancer, including certain blood or bone marrow disorders.
• People with a history of blood-related illnesses lasting more than 180 days, or who currently have such conditions.
• People with a history of heart-related conditions lasting more than 180 days, or who currently have such conditions.
• People with an untreated underactive thyroid.
• People who have been treated for tuberculosis (TB) within the past 90 days.
• People who currently have a breathing condition that requires supplemental oxygen.
• People who have taken certain immune-modifying medications (including maraviroc) in the 16 weeks before entering the study.
• People who have taken blood-thinning or anti-clotting medications in the 16 weeks before entering the study.
• People currently taking medications known to affect heart rhythm (QT interval).
• People with a close family member (parent, child, or sibling) with a known inherited heart rhythm condition called Long QT Syndrome.
• People currently taking certain medications that strongly affect how the body processes drugs (CYP3A4 interactions), including some specific HIV treatments such as protease inhibitors, efavirenz, etravirine, or cobicistat.
• People whose current substance use is likely to interfere with taking part in the study properly.
• People who are unable or unlikely to attend all required study visits and complete all assessments.
• People with a known allergy or sensitivity to dasatinib or any of its ingredients.
• People currently taking azithromycin, ondansetron, or pentamidine at the time of entering the study.

Important: Always verify eligibility with the trial site directly before applying.